CD155 and CD112 as possible therapeutic targets of <i>FLT3</i> inhibitors for acute myeloid leukemia.

CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia.

Kaito, Yuta; Hirano, Mitsuhito; Futami, Muneyoshi; Nojima, Masanori; Tamura, Hideto; Tojo, Arinobu; Imai, Yoichi.

Afiliación

Kaito Y; Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Hirano M; Department of Molecular Therapy, Advanced Clinical Research Center, The University of Tokyo, Tokyo 108-8639, Japan.
Futami M; Department of Molecular Therapy, Advanced Clinical Research Center, The University of Tokyo, Tokyo 108-8639, Japan.
Nojima M; Department of Translational Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Tamura H; Department of Hematology, Saitama Medical Center, Dokkyo Medical University, Saitama 343-8555, Japan.
Tojo A; Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Imai Y; Department of Molecular Therapy, Advanced Clinical Research Center, The University of Tokyo, Tokyo 108-8639, Japan.

Oncol Lett ; 23(2): 51, 2022 Feb.

Article en En | MEDLINE | ID: mdl-34992684